top of page

Home
Distributor Due Diligence Checklist
Pharma-Playbook
About
Services
Partners & Network
Resources
- Events
Schedule a call
More

Use tab to navigate through the menu items.

Knowledge Hub: Articles

Scroll to Events

All Posts
Business Development
Biosimilars
Generics
Oncology
Covid-19

Search

Commercial strategies for biosimilars: Any sense to register several brands?

Commercial strategies for biosimilars: Any sense to register several brands?

Commercial strategies for biosimilars: Any sense to register several brands?

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Oncology products will represent more than 20% of the German drug market. Can the system support it?

Oncology products will represent more than 20% of the German drug market. Can the system support it?

Oncology products will represent more than 20% of the German drug market. Can the system support it?

Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.

Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.

Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.

Notes on the German generics and biosimilars market 2016-2018.

Notes on the German generics and biosimilars market 2016-2018.

Notes on the German generics and biosimilars market 2016-2018.

Management (specific?) skills to succeed in pharmaceutical emerging markets.

Management (specific?) skills to succeed in pharmaceutical emerging markets.

Management (specific?) skills to succeed in pharmaceutical emerging markets.

Business Development

Events

Don't Miss Out on Our Events

Subscribe to our newsletter and stay in the loop

Add your email here

Thanks for submitting!

© Emergpharma
Contact

LinkedIn https://www.linkedin.com/in/j-ignacio-diaz/

Email: ignacio.diaz@emergpharmalinks.com

Jose Ignacio Diaz
Senior advisor

Copyright © 2023 Emergpharma Group. All rights reserved.

bottom of page